IL-17C as a Driver of Inflammation in Psoriasis
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03363-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Therapy, 2025. Verfasst von George Han und 3 weiteren Autor:innen. Beteiligte Einrichtung: NYC Health + Hospitals/Elmhurst, 79-01 Broadway, 718-334-4000, Elmhurst, NY, 11373, USA. george.han@nychhc.org. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Inflammation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Bausch Health Companies Inc..
Abstract (Originalsprache)
In psoriatic lesions, interleukin (IL)-17C protein expression has been reported as high as 125 times that of IL-17A; as such, it is crucial to understand the role that IL-17C plays in psoriasis, inflammation, and treatment response. Overexpression or injection of IL-17C in mice results in increased epidermal thickening and inflammation, whereas psoriatic mice with IL-17C knockout have decreased disease severity compared with control littermates. In psoriasis, IL-17C likely acts as a critical inflammatory amplifier via a feed-forward mechanism, wherein IL-17-producing CD4+ helper T (TH17) cells and IL-17-producing CD8+ cytotoxic T (TC17) cells stimulate IL-17C expression in keratinocytes. Then, keratinocyte-derived IL-17C induces IL-17A expression in TH17 and TC17 cells. Additionally, keratinocyte-derived IL-17C propagates its own signaling in an autocrine manner. Furthermore, studies suggest that IL-17C acts as an early mediator of psoriasis. No approved therapies directly target IL-17C. Brodalumab is an IL-17 receptor (IL-17R) A antagonist that inhibits IL-17A, F, C, and E signaling and has a unique mechanism of action among biologic therapies for psoriasis. By way of IL-17RA blockade, brodalumab is the only approved therapy for psoriasis that inhibits IL-17C signaling. This unique mechanism of action is hypothesized to correlate with efficacy in patients with prior failures to anti-IL-17A therapies and relatively higher rates of early skin clearance compared with those of other biologic therapies. Clinical studies are needed to confirm these correlations. In summary, IL-17C is an inflammatory amplifier and early psoriatic mediator, and inhibition of IL-17C may be beneficial in psoriasis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NYC Health + Hospitals/Elmhurst, 79-01 Broadway, 718-334-4000, Elmhurst, NY, 11373, USA. george.han@nychhc.org.
- University of California, Los Angeles, CA, USA.
- Rockefeller University, New York, NY, USA.
- Bausch Health Companies Inc, Bridgewater, NJ, USA.
Förderung
- Bausch Health Companies Inc.
Zitieren
APA
Han, G., Armstrong, A., Krueger, J. G., & Jacobson, A. (2025). IL-17C as a Driver of Inflammation in Psoriasis. Advances in Therapy. https://doi.org/10.1007/s12325-025-03363-9
Vancouver
Han G, Armstrong A, Krueger JG, Jacobson A. IL-17C as a Driver of Inflammation in Psoriasis. Advances in Therapy. 2025. doi:10.1007/s12325-025-03363-9
BibTeX
@article{Han2025,
author = {Han, George and Armstrong, April and Krueger, James G and Jacobson, Abby},
title = {IL-17C as a Driver of Inflammation in Psoriasis},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03363-9}
}
EUVIMED